The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions are listed in an approximately decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis , maceration of the skin , secondary infection , skin atrophy , striae, and miliaria. Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome , hyperglycemia , and glucosuria in some patients. In rare instances, treatment (or withdrawal of treatment) of psoriasis with corticosteroids is thought to have exacerbated the disease or provoked the pustular form of the disease, so careful patient supervision is recommended.
NINDS has established the NeuroNext clinical trials network to promote the rapid development and implementation of trials for neurological disorders that affect adults and/or children. Among its goals, the network is designed to develop early-phase trials aimed at identifying biomarkers-usually a physical trait or substance in the blood or other bodily fluids that can be measured to determine the presence and severity of a disease-and testing promising, emerging therapies. One of the first projects in this new network will hope to identify biomarkers for spinal muscular atrophy, which could speed the development of effective treatments for the disease.
Apply Taclonex ® Topical Suspension to areas affected by psoriasis 1 time a day for up to 8 weeks. You should stop treatment when your plaque psoriasis is under control, unless your doctor gives you other instructions. If you are 18 years of age or older, you should not use more than 100 grams of Taclonex ® Topical Suspension in 1 week. If you are 12 to 17 years of age, you should not use more than 60 grams of Taclonex ® Topical Suspension in 1 week. Use Taclonex ® Topical Suspension exactly as your doctor tells you to use it.